CAPN8: A Non-Coding RNA Molecule with Potential as A Drug Target Or Biomarker

Target Name: CAPN8

NCBI ID: G388743

CAPN8

CAPN8: A Non-Coding RNA Molecule with Potential as A Drug Target Or Biomarker

CAPN8, also known as NCL2, is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a non-coding RNA molecule that plays a critical role in the regulation of gene expression. Several studies have suggested that CAPN8 may have potential as a drug target or biomarker, and further research is needed to determine its full potential.

The NCL family of proteins is characterized by the presence of a nucleotide-binding oligomerization domain (NBO domain) and a conserved Co-repeat domain. NCL2 is a member of the NCL family and is expressed in various tissues of the body. It has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences and modulating the activity of RNA polymerase II.

One of the key functions of CAPN8 is its ability to interact with specific DNA sequences. Studies have shown that CAPN8 can bind to the alpha-helical region of the DNA double helix and the NBO domain can interact with the positive transcription factor, pRCH2. This interaction between CAPN8 and pRCH2 has been shown to play a role in the regulation of gene expression.

Another function of CAPN8 is its role in the regulation of microRNA (miRNA) expression. miRNA are small non-coding RNAs that play a critical role in post-transcriptional gene regulation by binding to specific target mRNAs. Studies have shown that CAPN8 can interact with the miRNA precursor RNA and prevent its processing and translation. This interaction between CAPN8 and miRNA has been shown to play a role in the regulation of gene expression.

CAPN8 has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. Studies have shown that CAPN8 can interact with the transcription factor, p16INK4a and can modulate its activity. This interaction between CAPN8 and p16INK4a has been shown to play a role in the regulation of cell apoptosis.

In addition to its role in gene expression, CAPN8 has also been shown to play a role in the regulation of cellular signaling pathways. Studies have shown that CAPN8 can interact with the protein, heat shock protein (Hsp) HSP70 and can modulate its activity. This interaction between CAPN8 and Hsp70 has been shown to play a role in the regulation of cellular signaling pathways.

CAPN8 has also been shown to have potential as a drug target. Several studies have shown that CAPN8 can interact with small molecules such as inhibitors of the NBO domain and can inhibit its activity. This interaction between CAPN8 and small molecules has been shown to play a role in the development of new anti-cancer drugs.

In conclusion, CAPN8 is a non-coding RNA molecule that plays a critical role in the regulation of gene expression, microRNA (miRNA) expression, cellular processes such as cell growth, apoptosis, and inflammation, and cellular signaling pathways. Its potential as a drug target or biomarker is under further investigation and future studies are needed to fully determine its full potential.

Protein Name: Calpain 8

Functions: Calcium-regulated non-lysosomal thiol-protease. Involved in membrane trafficking in the gastric surface mucus cells (pit cells) and may involve the membrane trafficking of mucus cells via interactions with coat protein. Proteolytically cleaves the beta-subunit of coatomer complex (By similarity)

The "CAPN8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CAPN8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets